Answers are grounded in this paper and cite their sources.
Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal MViV volumes and introduction of the SAPIEN 3 Ultra valve, it is important to determine contemporary outcomes for patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV replacement.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“If you’re just looking at short-term follow-up, 1 year or even 2 years, valve-in-valve is going to look better [because it’s] not a reop, it’s a stick in the groin. But when you follow out to 5 years, then you’ll see a survival benefit for surgery.”
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: